Lea en español

Zelnorm is the trade name for tegaserod, a 5-HT4 agonist used for the management of irritable bowel syndrome and constipation. The pharmaceutical company Novartis markets the prescription drug under the trade names Zelnorm in the U.S. and Zelmac in other countries.

In 2002, the Food and Drug Administration approved Zelnorm for short-term treatment of women with irritable bowel syndrome. Novartis amended its Zelnorm label in March 2004 to warn against the serious risk of diarrhea, ischemic colitis and death. In August 2004, the FDA further approved the prescription drug for men and women younger than 65 years of age with chronic constipation.

New released clinical trial data demonstrated an increased risk of serious adverse cardiovascular events, including heart attack, chest pain and stroke, associated with use of Zelnorm, Based on the recent data, the FDA requested Novartis remove Zelnorm from the market and issued a drug recall March 30, 2007.

The FDA advised patients taking Zelnorm to seek emergency medical care right away if they experience severe chest pain, shortness of breath, dizziness, sudden onset of weakness, difficulty walking or talking or other symptoms of a heart attack or stroke.

If you experienced a heart attack, stroke or other serious side effects while taking Zelnorm, you may be entitled to legal compensation for medical expenses, pain, suffering and loss of wages. You may have grounds for wrongful death lawsuit if a family member died from an adverse reaction to Zelnorm.

To learn more about legal claims relating to Zelnorm, consult an attorney who practices in the area of drugs and medical devices.